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Abstract
Background: Standards for reporting clinical trials have improved the transparency of patient-
important research. The Consolidated Standards of Reporting Trials (CONSORT) published an
extension to address noninferiority and equivalence trials. We aimed to determine the reporting
quality of prostaglandin noninferiority and equivalence trials in the treatment of glaucoma.
Methods: We searched, independently and in duplicate, 6 electronic databases for eligible trials
evaluating prostaglandins. We abstracted data on reporting of methodological criteria, including
reporting of per-protocol [PP] and intention-to-treat [ITT] analysis, sample size estimation with
margins, type of statistical analysis conducted, efficacy summaries, and use of hyperemia measures.
Results: Trials involving the four major prostaglandin groups (latanoprost, travoprost,
bimatoprost, unoprostone) were analyzed. We included 36 noninferiority and 11 equivalence trials.
Seventeen out of the included 47 trials (36%, 95% Confidence Intervals [CI]: 24–51) were
crossover designs. Only 3 studies (6%, 95% CI: 2–17) reported a presented results of both ITT and
PP populations. Twelve studies (26%, 95% CI: 15–39) presented only ITT results but mentioned
that PP population had similar results. Thirteen trials (28%, 95% CI: 17–42) presented only PP
results with no mention of ITT population results while 17 studies (36%, 95% CI: 24–51) presented
only ITT results with no mention of PP population results. Thirty-four (72%, 95% CI: 58–83) of
studies adequately described their margin of noninferiority/equivalence. Sequence generation was
reported in 22/47 trials (47%, 95% CI: 33–61). Allocation concealment was reported in only 10/47
(21%, 95% CI: 12–35) of the trials. Thirty-five studies (74%, 95% CI: 60–85) employed masking of
at least two groups, 4/47 (9%, 95% CI: 3–20) masked only patients and 8/47 (17%, 95% CI: 9–30)
were open label studies. Eight (17%, 95% CI: 9–30) of the 47 trials employed a combined test of
noninferiority and superiority. We also found 6 differing methods of evaluating hyperemia.
Conclusion: The quality of reporting noninferiority/equivalency trials in the field of glaucoma is
markedly heterogeneous. The adoption of the extended CONSORT statement by journals will
potentially improve the transparency of this field.
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There is emerging debate about the adherence to stand-
ards or recommendations made by regulatory bodies in
the design, statistical analysis, description, and reporting
of randomised clinical trials (RCT) intended to show non-
inferiority or equivalence [1]. The recent extension of the
Consolidated Standards of Reporting Trials (CONSORT)
statement to noninferiority and equivalence trials [1], the
U. S. Food and Drug Administration (FDA) guidelines [2],
as well as statements from other regulatory authorities,
have updated recommendations to guide the conduct and
reporting of RCTs investigating noninferiority or equiva-
lence [3].
Noninferiority and equivalence studies aim to demon-
strate that a new experimental treatment is not statistically
worse than the active control intervention by more than a
pre-specified amount (Δ), the noninferiority or equiva-
lence margin. There are now a large number of studies
intending to demonstrate noninferiority or equivalence.
However, only very few of them have been designed,
described, and reported as such [4]. In designs intending
to show noninferiority (i.e. that a new treatment is at least
as good as or no worse than an existing treatment) or
equivalence (i.e. show that a new treatment has equal or
comparable efficacy effects), one area of debate has been
the application of the intent-to-treat (ITT) principle versus
the per-protocol (PP) analysis [5]. There has been an
expectation that ITT analyses are less conservative, tending
to reduce the observed treatment difference in noninferi-
ority trials, thus permitting wider confidence intervals; a
factor that has increased the dependence on per-protocol
analysis. The International Conference on Harmonization
of Technical Requirements for Registration of Pharmaceu-
ticals for Human Use (ICH) E9 guideline on 'statistical
principles for clinical trials' unequivocally states that the
use of the ITT analysis in equivalence and noninferiority
trials is 'generally not conservative and its role should be
considered very carefully' [6]. However, the Committee
for Proprietary Medicinal Products (CPMP) consider both
analyses to be equally important [7] and simulation stud-
ies have not demonstrated the anticonservative approach
of ITT versus PP [8]. In the extension of the CONSORT
statement, conducting and reporting PP analyses along-
side ITT has been suggested as a means of increasing con-
fidence in the study finding particularly when both
methods produce similar results.
In order to determine the methodological quality and
reporting standards for those trials designed to show non-
inferiority or therapeutic equivalence, we conducted a sys-
tematic survey of the literature to identify noninferiority
and equivalence randomised clinical trials involving glau-
coma drugs of prostaglandin origin. We applied the
extended CONSORT statement for non-inferiority and




Noninferiority and equivalence randomized clinical trials
that involved the application of any of the four major
drugs of the prostaglandin analogues (latanoprost, travo-
prost, bimatoprost, and unoprostone) in the treatment of
patients with open angle glaucoma (POAG) or ocular
hypertension (OH) were eligible for the study. We defined
noninferiority trials as 1-sided trials aiming to demon-
strate effectiveness not lower than Δ. Whereas, equiva-
lence studies were defined as 2-sided trials wherein the
difference between treatments is between -Δ and +Δ mar-
gins of equivalence. We further determined a trial to be
eligible for inclusion if 'equivalence' or 'noninferiority'
was mentioned as the intent anywhere in the methods
sections of the manuscripts. We excluded bioequivalence
(pharmacokinetic and pharmacodynamic) trials and trials
designed to show superiority.
Search Strategy
Using independent and duplicate searchers (OE, EM), we
searched the following 6 databases from inception to
March 2008: MEDLINE via PubMed, CinAhl, AMED,
Toxnet, Cochrane CENTRAL and E-Psyche. Our MEDLINE
search strategy identified the exact MeSH terms for the fol-
lowing expressions: open angle glaucoma, ocular hyper-
tension and prostaglandin* (latanoprost, bimatoprost,
travoprost aand unoprostone). We conducted 3 main
searches. First we collated all articles with the MeSH key
terms "glaucoma, open angle OR ocular hypertension"
[see Additional file 1]. We then extracted articles contain-
ing the MeSH terms "prostaglandin* OR latanoprost OR
travoprost OR bimatoprost OR unoprostone." We then
pooled these two searches to produce a third list, repre-
senting all articles that had as its key terms, "POAG or OH
or prostaglandin* OR latanoprost OR travoprost OR
bimatoprost OR unoprostone." We also searched multi-
ple databases including CinAhl, AMED, Toxnet, Cochrane
CENTRAL and E-Psyche using key search terms like latan-
oprost, bimatoprost, travoprost, unoprostone, open angle
glaucoma, ocular hypertension and prostaglandin*.
Simultaneous review of these databases was possible
through the use of the Ovid interdisciplinary database
that permits the checking of multiple databases. Where
full text was unavailable, we searched Google Scholar and
also used interlibrary loans to order full text articles. We
supplemented this search by reviewing the bibliographies
of key papers.
Study selection
Working independently and in duplicate OE and EM
reviewed all abstracts and full articles, where available, ofPage 2 of 9
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were not randomized trials or were reviews and/or com-
ments. All full text articles of identified RCT studies that
examined treatment with prostaglandin drugs were
sought. Eligibility was determined in consensus. Only
comparisons containing at least one study drug of interest
(i.e., bimatoprost, latanoprost, travoprost or unopros-
tone) were eligible for inclusion. When comparisons
involved several different dosages (e.g., 0.005% or
0.03%), we included only those that met FDA-approved
standards. Where we were unsure of specific intentions of
noninferiority/equivalence compared to superiority, we
contacted one author via email.
Data Collection
We collected information about the type of interventions
tested, study design and purpose. We also obtained data
on sample size estimation with margins, type of statistical
analysis conducted, population analyzed [ITT or/and PP],
efficacy summaries, and use of hyperemia measures. Our
study evaluation included an assessment of the following
general methodological quality features: allocation con-
cealment, sequence generation, masking status, and the
handling of losses to follow-up. We also recorded sample
size (recruited, randomized and completed) and the use
of a combined test of noninferiority and superiority.
Finally, we noted whether there was a clear objective/
hypothesis relating to noninferiority or equivalence, a tab-
ular presentation of baseline data (demographic and clin-
ical), and a predetermined noninferiority/equivalence
margin.
Data Analysis
In order to assess inter-rater reliability on inclusion of arti-
cles, we calculated the Phi statistic, which provides a meas-
ure of inter-observer agreement independent of chance
[9]. In order to determine the proportion reporting the
specific item with appropriate confidence intervals, we
first stabilized the variances of the raw proportions (r/n)
using a Freeman-Tukey type arcsine square root transfor-
mation: y = arcsine (square root(r/(n+1))+arcsine(square
root(r+1)/(n+1))), with a variance of 1/(n+1), where n is
the denominator overall size [10]. We used StatsDirect
(version 2.5.2, http://www.statsdirect.com for all calcula-
tions.
Results
Results of literature search
Our first and second search produced 35,207 and 97,523
abstracts respectively. The third and final search (search
#1 AND #2 pooled) produced 1144 abstracts. After thor-
ough assessment, 215 abstracts were excluded since they
were review articles. Another 549 abstracts were excluded
as they were not relevant to present study. Overall, 380
full text papers were retrieved for possible inclusion.
Upon careful review of the 380 full text articles, we
included 47 full text articles in our analysis (Phi = 0.88).
Figure 1 presents details of the exclusion criteria at the var-
ious stages during the study selection process.
Trial interventions
Table 1 outlines the characteristics of all 47 included pub-
lications. Of these, 31 reported conducting comparisons
of treatments (e.g., travoprost vs. latanoprost) that were
duplicated in at least one other included study. More spe-
cifically, five trials compared bimatoprost to latanoprost
[11-15]. Four trials compared bimatoprost and timolol
[16-19]. Three trials compared bimatoprost to a fixed
combination (FC) treatment that contained timolol [20-
22].
Six trials compared latanoprost to timolol [13,23-27].
Three studies compared latanoprost to brimonidine (or
brimonidine-containing fixed combination) [28-30]. Two
studies compared FC latanoprost/timolol vs FC dorzola-
mide/timolol [31,32]. Two studies compared FC latano-
prost/timolol versus its individual components (i.e.
latanoprost and timolol) [33,34]. Two studies compared
FC latanoprost/timolol versus latanoprost and timolol
administered concomitantly [35,36].
Four studies compared travoprost and latanoprost
[12,13,23,37]. Two studies compared travoprost and
timolol [23,38]. Two studies compared travoprost or FC-
containing travoprost versus latanoprost (or FC-contain-
ing latanoprost) [39,40] and three studies compared tra-
voprost or FC-containing travoprost versus timolol (or
FC-containing timolol) [39-41]. Finally, 16 publications
contained other comparisons of treatment types that were
not duplicated with any other included study. [42-57]
Characteristics of trials
Table 2 shows the characteristics of the trials as well as the
quality of reporting. The average sample size was 311 (SD
33), although on average, only 86% of patients were
included in the final analyses. Seventeen out of the
included 47 trials (36%, 95% CI: 24–51) were crossover
designs.
Of the 47 trials, 36 were noninferiority trials (77%, 95%
CI: 63–86) and 11 (23%, 95% CI: 14–37) were designed
for equivalence. In the final interpretations of the studies,
16/47 (34%, 95% CI: 22–48) trials claimed noninferior-
ity, 14/47 (30%, 95% CI: 19–44) claimed equivalence
and 17/47 (36%, 95% CI: 24–51) claimed superiority. For
the trials claiming noninferiority, 33/36 (92%, 95% CI:
78–92) were accurate within their noninferiority margin.
For those claiming equivalency, 10/11 (90%, 95% CI: 62–
98) were accurate within their a priori margins. SeventeenPage 3 of 9
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bined test of noninferiority and superiority.
Sequence generation was reported in 22/47 trials (47%,
95% CI: 33–61). Allocation concealment was reported in
only 10/47 (21%, 95% CI: 12–35) of the trials. Thirty-five
studies (74%, 95% CI: 60–85) employed masking of at
least two groups, 4/47 (9%, 95% CI: 3–20) masked only
patients and 8/47 (17%, 95% CI: 9–30) were open label
studies.
Only 6 of the 47 (13%, 95% CI: 6–25) studies specified
that the trial was a noninferiority or equivalence trial in
the title or abstract. The background or introduction sec-
tion of 5/47 (11%, 95% CI: 5–23) articles contained a
rationale for using a noninferiority or equivalence trial
design. Thirteen articles (28%, 95% CI: 17–42) had a clear
objective or hypothesis pertaining to noninferiority or
equivalence. Thirty-four trials (72%, 95% CI: 58–83)
properly described the method applied in the sample size
determination and set appropriate boundaries on nonin-
feriority or equivalence. The pre-stated noninferiority/
equivalence in all the trials lied between the ranges of -1
to 2.5. Primary outcome measure was the mean intraocu-
lar pressure which was mostly measured as a mean differ-
ence or as a mean reduction from baseline.
Only 3/47 (6%, 95% CI: 2–17) studies reported and pre-
sented results of both ITT and PP populations. Two stud-
ies (4%, 95% CI: 1–14) presented only PP results but
mentioned that ITT population had similar results. Twelve
studies (26%, 95% CI: 15–39) presented only ITT results
but mentioned that PP population had similar results.
Thirteen trials (28%, 95% CI: 17–42) presented only PP
results with no mention of ITT population results while
17/47 (36%, 95% CI: 24–51) studies presented only ITT
results with no mention of PP population results.
From the 47 trials reported in this study, only one (2%,
95% CI: 0.5–11) diagrammatically presented its results by
use of a figure showing the confidence intervals and pre-
specified margins of equivalence or noninferiority. Han-
dling of losses to follow-up was not addressed in 33 of the
47 trials (70%, 95% CI: 56–81). Loss to follow-up was
mentioned but unaddressed in 10 trials (21%, 95% CI:
12–35), while 3/47 (6%, 95% CI: 2–17) were addressed
in the statistics and 1/47 (2%, 95% CI: 0–11) had a zero
loss to follow-up.
Measurement of hyperemia
We found large heterogeneity of measuring hyperemia.
Two of the 47 (4%, 95% CI: 1–14) included studies used
a severity scale based on non-serious, mild, moderate, and
serious. Six studies (13%, 95% CI: 6–25) used a severity
scale based on none, mild, moderate, and serious. Five
(11%, 95% CI: 5–23) used a scale that recorded only
mild, moderate, and severe. One (2%, 95% CI: 0.5–11)
used a scale that included only non-serious and serious.
One (2%, 95% CI: 0.5–11) used a four-point scale from
1–4 stating minimum and maximum as the scale end-
points. Six (13%, 95% CI:6–25) studies used a 5 point
scale with 0 = none, 0.5 = trace, 1 = mild, 2 = moderate,
and 3 severe. A further 26/47 (55%, 95% CI: 41–69) did
not report their method of measuring hyperemia, of
which 5/26 (19%, 95% CI: 9–38) did not report on hyper-
emia outcomes.
Discussion
To our knowledge, this is the first study that has attempted
to look into the methodological quality and reporting of
any ophthalmology RCTs designed to show noninferior-
ity or equivalence for glaucoma treatments. These findings
reinforce the gaps that exist in the methodological quality
and reporting of these trials in general. We additionally
found that within ophthalmology trials, a substantial het-
erogeneity exists in terms of measuring clinical outcomes,
such as hyperemia. It is clear that further efforts at improv-
ing the reporting and analyses of clinical trials in this field
are needed. Recent work by Hopewell and colleagues [58]
highlighted the need for journals to endorse the CON-
SORT Statement and its extensions, and also make its
application a condition for authors wishing to publish in
the journal. Journals in the ophthalmology field should
consider such an endorsement as well as promoting a
Flow diagram of included studiesigure 1
Flow diagram of included studies
1144 abstracts were screened for 
inclusion 
215 review articles/meta-analysis 
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380 full text papers retrieved for 
possible inclusion 
549 abstracts excluded as irrelevant 
(i.e non-randomised trials, case 
studies, observational studies, etc) 
87 articles excluded (comments, 
editorials, letters) 
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(not a POAG or OH study, non-
prostaglandin treatment; 1 article 
with pooled data from earlier study) 
47 full text publications included 
6 articles with full text in non-
English language were excluded  
159 papers excluded on two 
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order to potentially improve manuscript reporting.
There are several strengths and limitations to consider in
interpreting our study. Strengths include our extensive
searching of the literature to identify a representative sam-
ple of a field that commonly utilizes noninferiority and
equivalence trials. Our data abstraction methods aimed to
reduce investigator driven bias with duplicate data
abstraction. Limitations to consider include that we solely
Table 1: Characteristics of included publications
Author Year Sample Size
(N completed)
Treatment Comparison
Topouzis et al [40] 2007 332 Travoprost 0.004%/timolol 0.5% versus once-daily latanoprost 0.005%/timolol 0.5%
Hommer [43] 2007 430 FC bimatoprost 0.03%/timolol 0.5% versus non-FC bimatoprost 0.03%/timolol 0.5%
Hollo et al [44] 2006 192 Timolol maleate versus brinzolamide both added to travoprost
Brittain et al [20] 2006 46 Combination timolol 0.5% and latanoprost 0.005% versus bimatoprost 0.03%
Day et al [21] 2005 32 bimatoprost 0.03% versus timolol maleate 0.5%/dorzolamide 2% FC
Netland et al [45] 2003 25 Brimonidine purite + bimatoprost versus timolol + latanoprost
Thomas et al [28] 2003 26 Latanoprost versus brimonidine
Whitcup et al [16] 2003 550 Bimatoprost versus timolol
Netland et al [23] 2001 760 Travoprost versus latanoprost versus timolol
Larsson [24] 2001 24 Latanoprost 0.005% versus timolol gel-forming solution 0.5%
Fechtner et al [42] 2004 238 FC dorzolamide 2%/timolol 0.5% (COSOPT™) versus latanoprost 0.005% (XALATAN™)
Cohen et al [17] 2004 284 Bimatoprost versus timolol
Shin et al [31] 2004 242 FC latanoprost/timolol versus FC dorzolamide/timolol
Tomita et al [25] 2004 39 Latanoprost versus timolol
Stewart et al [46] 2004 32 Latanoprost/timolol maleate FC versus concomitant brimonidine and latanoprost therapy
Gandolfi et al [11] 2001 214 Bimatoprost versus latanoprost
Watson et al [26] 1996 268 Latanoprost versus timolol
Konstas et al [57] 2002 35 Once-daily morning versus evening dosing of concomitant latanoprost/timolol
Day et al [47] 2003 31 Timolol 0.5%/Dorzolamide 2% FC versus timolol maleate 0.5% and unoprostone...
Parrish et al [12] 2003 410 Latanoprost versus bimatoprost versus Travoprost
Konstas et al [32] 2004 32 FC latanoprost 0.005%/timolol maleate 0.5% versus FC dorzolamide 2%/timolol maleate 0.5%
Sharpe et al [48] 2005 29 Brimonidine 0.2% versus unoprostone 0.15% both added to timolol maleate 0.5%
Higginbotham et al [18] 2002 1009 Bimatoprost versus timolol
Pfeiffer [33] 2002 396 FC latanoprost and timolol versus its individual components
Higginbotham et al [34] 2002 345 FC latanoprost and timolol versus monotherapy with either components
Konstas et al [49] 2008 53 Latanoprost and dorzolamide/timolol FC after 2 and 6 months of treatment
Konstas et al [37] 2007 40 Latanoprost versus travoprost
Franks et al [39] 2006 106 Travoprost 0.004% versus FC latanoprost 0.005%/timolol 0.5%
Diestelhorst et al [35] 2006 502 FC latanoprost and timolol in the evening versus concomitant use of the individual 
components
Hughes et al [41] 2005 293 FC travoprost 0.004%/timolol 0.5% ophthalmic solution versus concomitant use of the 
individual components
Schuman et al [50] 2005 387 FC travoprost 0.004%/timolol 0.5% versus concomitant travoprost 0.004% + timolol 0.5 
versus timolol BID control
Konstas et al [29] 2005 31 Brimonidine purite versus dorzolamide each added to latanoprost
Diestelhorst et al [36] 2004 190 FC latanoprost/timolol versus concomitant latanoprost and timolol
Coleman et al [22] 2003 168 Bimatoprost (LUMIGAN) versus combined timolol and dorzolamide (COSOPT)
Zimmerman et al [13] 2003 2775 Various POAG monotherapy versus latanoprost
Stewart et al [51] 2003 29 FC timolol maleate/latanoprost versus timolol maleate + brimonidine
Noecker et al [14] 2003 249 Bimatoprost versus latanoprost
Honrubia et al [52] 2002 217 Latanoprost 0.005% versus FC dorzolamide 2% & timolol 0.5%
Simmons et al [30] 2002 107 Brimonidine versus latanoprost in patients uncontrolled on β – blockers
Goldberg et al [38] 2001 507 Topical travoprost versus timolol BID
DuBiner et al [15] 2001 59 Bimatoprost versus latanoprost
Brandt et al [19] 2001 556 QD, BID bimatoprost versus timolol BID
Susanna et al [53] 2001 98 Latanoprost versus unoprostone
Diestelhorst et al [54] 2000 179 Latanoprost versus pilocarpine T.I.D
Stewart et al [55] 1999 30 Timolol solution versus timolol gel each added to latanoprost
Konstas et al [27] 1999 34 Latanoprost versus timolol maleate
Petounis et al [56] 2001 148 Latanoprost versus dorzolamide each added to timololPage 5 of 9
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Table 2: Methodological quality and reporting
Characteristics Number of studies with 
characteristics
% of studies with characteristics 95% Confidence Interval
Crossover studies 17 36 24, 51
Parallel treatment studies 30 64 49, 76
Title and Abstract specifying that trial 
is a noninferiority or equivalence trial
6 13 6, 25
Articles whose background or 
introduction section contains a 
rationale for using a noninferiority or 
equivalence trial design
5 11 5, 23
Articles with a clear objective or 
hypothesis pertaining to 
noninferiority or equivalence
13 28 17, 42
Sample size determination: Studies 
that appropriately described how the 
sample size was determined*
34 72 58, 83
Randomization: Studies stating the 
methods used in the generation of the 
random allocation sequence
22 47 33, 61
Masking:
Two or more groups 35 75 60, 85
Patients only 4 9 3, 20
Open label studies 
(i.e. studies that were not masked)
8 17 9, 30
Allocation concealment: Studies 
reporting this characteristic
10 21 12, 35
Statistical methods and numbers 
analyzed:
Studies that employed the 
combined test of noninferiority 
and superiority
8 17 9, 30
Studies presenting results of only 
ITT population with no mention of 
PP population
17 36 24, 51
Studies presenting results of only 
PP population with no mention of 
ITT population
13 28 17, 42
Studies presenting only results of 
ITT population but mentioned that 
PP produced similar results
12 26 15, 39
Studies presenting only results of 
PP population but mentioned that 
ITT produced similar results
2 4 1, 14
Studies reporting and presenting 
results of both ITT and PP 
populations
3 6 2, 17
Results:
Studies presenting a figure showing 
the range of the confidence interval 
relative to the pre-specified 
noninferiority/equivalence margin
1 2 0.5, 11
* = appropriate sample size determination stating all of the following; a predetermined noninferiority or equivalence margin, standard deviation used, 
significance level [α], and the power used
Trials 2008, 9:69 http://www.trialsjournal.com/content/9/1/69relied upon the reporting of specific items rather than
inquiring about any missing items through contact with
each individual trial investigator. As outlined in the meth-
ods, study authors were only contacted when we were
unclear whether the trial itself included a non-inferiority
or equivalence study design. It is possible that some of the
specific methodological items were conducted but not
reported. Indeed, this issue has been highlighted by inves-
tigators [59]. However, our study aimed to determine
reporting quality in order to make specific recommenda-
tions on transparent reporting. We did not determine
changes pre- versus post-publication of the extended
CONSORT statement in 2006. Previous research has
found that the quality of reports improved after publica-
tion of the original 1996 CONSORT publication [60]. Per-
protocol analyses have traditionally been preferred over
ITT approaches despite current consensus of displaying
both [1,4,7]. In our study we were unable to determine if
one is superior to the other as we found too few examples
where both outcomes are reported.
The findings of our study are consistent with other studies
investigating reporting quality in general medicine jour-
nals and specialist journals [61]. General medicine jour-
nals tend to report important methodological
recommendations more frequently than specialist jour-
nals. This may be due to the encouragement of journals to
utilize the CONSORT recommendations through editori-
als and letters [62]. Providing editorials or guidelines in
the instructions to authors is a potential option for
improving the reporting of these RCTs. An option that
may be considered is a checklist submitted with clinical
trials indicating where in the manuscript specific details
are reported, as required by many current journals.
An important methodological issue that has been raised
by this review is the use of a combined test of noninferi-
ority and superiority. The purpose of conducting noninfe-
riority and equivalence trials is not to evaluate superiority,
as that would require far more power than would be
expected in this type of trial and would maintain the need
for ITT analysis [63]. In our study, 8 trials employed the
combined test for noninferiority and superiority. This
allows a trial to claim its original intent of noninferiority
if superiority is not identified, but can claim superiority if
the arbitrary threshold, upper-limit of noninferiority, is
surpassed [64].
Given the heated market of the prostaglandin field, we
found that several (n = 17) noninferiority and equivalence
trials claimed superiority of the test intervention over
competitors products, regardless of overall findings and
the study intent. For example, in a randomized trial eval-
uating travoprost to latanoprost on 408 patients' daily
intraocular pressure at 9 am, 11 am and 4 pm, the authors
found noninferiority, but report on statistical superiority
at the 9 am measurement [40]. Given the lack of ITT anal-
ysis, the multiple testing and initial intention of a nonin-
feriority analysis, such findings provide misleading
evaluations of superiority. Indeed, this phenomenon
exists across a range of medical fields [65-70].
Pre-specifying the noninferiority or equivalence margin is
necessary to provide strong inferences about the suitabil-
ity of one treatment compared to another. If the margin
employed is too wide, risk for type 1 error exists. Similarly,
although unlikely, if one were to establish the margin too
narrow, a type 2 error is possible. Margins should be
established based on clinical justification and not statisti-
cal rule [71].
Conclusion
In conclusion, based on the analysis of the study reports
that we have examined, our findings demonstrate defi-
ciencies in the design, planning, and reporting of nonin-
feriority and equivalence trials in the ophthalmology
literature. Many studies of clinical noninferiority and
equivalence do not set boundaries for equivalence.
Claims of "superiority" and "similarity" are often dis-
played despite the use of improper analysis. These meth-
odologic deficiencies appear to lead to false claims,
unrepeatable experiments, and possible costs or harms to
patients.
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